Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature;Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature (Endocrine DOI: 10.1007/s12020-014-0179-0)

Endocrine

Volumn 46, Issue 3, 2014, Pages 420-422

  Giorda, Carlo B ^a   Nada, Elisa ^b   Tartaglino, Barbara ^b  

^a ASL TO5   (Italy)

^b Chaira Medica Association   (Italy)

Author keywords

Hepatic impairment; Efficacy; Renal impairment; Safety; Incretins or DPP 4 inhibitors or GLP 1 receptor agonists

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL;

EID: 84904577545     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0179-0     Document Type: Review

References (2)

1. J.C. Arjona Ferreira, D. Corry, C.E. Mogensen, L. Sloan, L. Xu, G.T. Golm, E.J. Gonzalez, M.J. Davies, K.D. Kaufman, B.J. Goldstein, Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 61(4), 579-587 (2013)
2. J.C. Arjona Ferreira, M. Marre, N. Barzilai, H. Guo, G.T. Golm, C.M. Sisk, K.D. Kaufman, B.J. Goldstein, Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 36(5), 1067-1073 (2013)